Global Drugs of UDCA and t-UDCA Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Description

According to our (Global Info Research) latest study, the global Drugs of UDCA and t-UDCA market size was valued at US$ 2203 million in 2024 and is forecast to a readjusted size of USD 4971 million by 2031 with a CAGR of 12.5% during review period. 
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.,Ursodeoxycholic Acid is an important clinical drug in the treatment of gallstones, cholecystitis, PBC, and PSC and has broad market prospects. In previous work, ursodeoxycholic acid was prepared by traditional organic synthesis.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report is a detailed and comprehensive analysis for global Drugs of UDCA and t-UDCA market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:
Global Drugs of UDCA and t-UDCA market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Drugs of UDCA and t-UDCA market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Drugs of UDCA and t-UDCA market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Drugs of UDCA and t-UDCA market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Drugs of UDCA and t-UDCA
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Drugs of UDCA and t-UDCA market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Viatris, Bruschettini, Impax, Shanghai Pharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation
Drugs of UDCA and t-UDCA market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    t-UDCA
    UDCA

Market segment by Application
    Gallstone
    Hepatopathy
    Biliary Disease
    Other

Major players covered
    Dr. Falk Pharma
    Daewoong Pharmaceutical
    Teva
    Epic Pharma
    Mitsubishi Tanabe Pharma
    Lannett
    Viatris
    Bruschettini
    Impax
    Shanghai Pharma
    Grindeks

Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs of UDCA and t-UDCA product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Drugs of UDCA and t-UDCA, with price, sales quantity, revenue, and global market share of Drugs of UDCA and t-UDCA from 2020 to 2025.
Chapter 3, the Drugs of UDCA and t-UDCA competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs of UDCA and t-UDCA breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Drugs of UDCA and t-UDCA market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Drugs of UDCA and t-UDCA.
Chapter 14 and 15, to describe Drugs of UDCA and t-UDCA sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Drugs of UDCA and t-UDCA Consumption Value by Type: 2020 Versus 2024 Versus 2031
        1.3.2 t-UDCA
        1.3.3 UDCA
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Drugs of UDCA and t-UDCA Consumption Value by Application: 2020 Versus 2024 Versus 2031
        1.4.2 Gallstone
        1.4.3 Hepatopathy
        1.4.4 Biliary Disease
        1.4.5 Other
    1.5 Global Drugs of UDCA and t-UDCA Market Size & Forecast
        1.5.1 Global Drugs of UDCA and t-UDCA Consumption Value (2020 & 2024 & 2031)
        1.5.2 Global Drugs of UDCA and t-UDCA Sales Quantity (2020-2031)
        1.5.3 Global Drugs of UDCA and t-UDCA Average Price (2020-2031)

2 Manufacturers Profiles
    2.1 Dr. Falk Pharma
        2.1.1 Dr. Falk Pharma Details
        2.1.2 Dr. Falk Pharma Major Business
        2.1.3 Dr. Falk Pharma Drugs of UDCA and t-UDCA Product and Services
        2.1.4 Dr. Falk Pharma Drugs of UDCA and t-UDCA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.1.5 Dr. Falk Pharma Recent Developments/Updates
    2.2 Daewoong Pharmaceutical
        2.2.1 Daewoong Pharmaceutical Details
        2.2.2 Daewoong Pharmaceutical Major Business
        2.2.3 Daewoong Pharmaceutical Drugs of UDCA and t-UDCA Product and Services
        2.2.4 Daewoong Pharmaceutical Drugs of UDCA and t-UDCA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.2.5 Daewoong Pharmaceutical Recent Developments/Updates
    2.3 Teva
        2.3.1 Teva Details
        2.3.2 Teva Major Business
        2.3.3 Teva Drugs of UDCA and t-UDCA Product and Services
        2.3.4 Teva Drugs of UDCA and t-UDCA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.3.5 Teva Recent Developments/Updates
    2.4 Epic Pharma
        2.4.1 Epic Pharma Details
        2.4.2 Epic Pharma Major Business
        2.4.3 Epic Pharma Drugs of UDCA and t-UDCA Product and Services
        2.4.4 Epic Pharma Drugs of UDCA and t-UDCA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.4.5 Epic Pharma Recent Developments/Updates
    2.5 Mitsubishi Tanabe Pharma
        2.5.1 Mitsubishi Tanabe Pharma Details
        2.5.2 Mitsubishi Tanabe Pharma Major Business
        2.5.3 Mitsubishi Tanabe Pharma Drugs of UDCA and t-UDCA Product and Services
        2.5.4 Mitsubishi Tanabe Pharma Drugs of UDCA and t-UDCA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.5.5 Mitsubishi Tanabe Pharma Recent Developments/Updates
    2.6 Lannett
        2.6.1 Lannett Details
        2.6.2 Lannett Major Business
        2.6.3 Lannett Drugs of UDCA and t-UDCA Product and Services
        2.6.4 Lannett Drugs of UDCA and t-UDCA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.6.5 Lannett Recent Developments/Updates
    2.7 Viatris
        2.7.1 Viatris Details
        2.7.2 Viatris Major Business
        2.7.3 Viatris Drugs of UDCA and t-UDCA Product and Services
        2.7.4 Viatris Drugs of UDCA and t-UDCA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.7.5 Viatris Recent Developments/Updates
    2.8 Bruschettini
        2.8.1 Bruschettini Details
        2.8.2 Bruschettini Major Business
        2.8.3 Bruschettini Drugs of UDCA and t-UDCA Product and Services
        2.8.4 Bruschettini Drugs of UDCA and t-UDCA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.8.5 Bruschettini Recent Developments/Updates
    2.9 Impax
        2.9.1 Impax Details
        2.9.2 Impax Major Business
        2.9.3 Impax Drugs of UDCA and t-UDCA Product and Services
        2.9.4 Impax Drugs of UDCA and t-UDCA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.9.5 Impax Recent Developments/Updates
    2.10 Shanghai Pharma
        2.10.1 Shanghai Pharma Details
        2.10.2 Shanghai Pharma Major Business
        2.10.3 Shanghai Pharma Drugs of UDCA and t-UDCA Product and Services
        2.10.4 Shanghai Pharma Drugs of UDCA and t-UDCA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.10.5 Shanghai Pharma Recent Developments/Updates
    2.11 Grindeks
        2.11.1 Grindeks Details
        2.11.2 Grindeks Major Business
        2.11.3 Grindeks Drugs of UDCA and t-UDCA Product and Services
        2.11.4 Grindeks Drugs of UDCA and t-UDCA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.11.5 Grindeks Recent Developments/Updates

3 Competitive Environment: Drugs of UDCA and t-UDCA by Manufacturer
    3.1 Global Drugs of UDCA and t-UDCA Sales Quantity by Manufacturer (2020-2025)
    3.2 Global Drugs of UDCA and t-UDCA Revenue by Manufacturer (2020-2025)
    3.3 Global Drugs of UDCA and t-UDCA Average Price by Manufacturer (2020-2025)
    3.4 Market Share Analysis (2024)
        3.4.1 Producer Shipments of Drugs of UDCA and t-UDCA by Manufacturer Revenue ($MM) and Market Share (%): 2024
        3.4.2 Top 3 Drugs of UDCA and t-UDCA Manufacturer Market Share in 2024
        3.4.3 Top 6 Drugs of UDCA and t-UDCA Manufacturer Market Share in 2024
    3.5 Drugs of UDCA and t-UDCA Market: Overall Company Footprint Analysis
        3.5.1 Drugs of UDCA and t-UDCA Market: Region Footprint
        3.5.2 Drugs of UDCA and t-UDCA Market: Company Product Type Footprint
        3.5.3 Drugs of UDCA and t-UDCA Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Drugs of UDCA and t-UDCA Market Size by Region
        4.1.1 Global Drugs of UDCA and t-UDCA Sales Quantity by Region (2020-2031)
        4.1.2 Global Drugs of UDCA and t-UDCA Consumption Value by Region (2020-2031)
        4.1.3 Global Drugs of UDCA and t-UDCA Average Price by Region (2020-2031)
    4.2 North America Drugs of UDCA and t-UDCA Consumption Value (2020-2031)
    4.3 Europe Drugs of UDCA and t-UDCA Consumption Value (2020-2031)
    4.4 Asia-Pacific Drugs of UDCA and t-UDCA Consumption Value (2020-2031)
    4.5 South America Drugs of UDCA and t-UDCA Consumption Value (2020-2031)
    4.6 Middle East & Africa Drugs of UDCA and t-UDCA Consumption Value (2020-2031)

5 Market Segment by Type
    5.1 Global Drugs of UDCA and t-UDCA Sales Quantity by Type (2020-2031)
    5.2 Global Drugs of UDCA and t-UDCA Consumption Value by Type (2020-2031)
    5.3 Global Drugs of UDCA and t-UDCA Average Price by Type (2020-2031)

6 Market Segment by Application
    6.1 Global Drugs of UDCA and t-UDCA Sales Quantity by Application (2020-2031)
    6.2 Global Drugs of UDCA and t-UDCA Consumption Value by Application (2020-2031)
    6.3 Global Drugs of UDCA and t-UDCA Average Price by Application (2020-2031)

7 North America
    7.1 North America Drugs of UDCA and t-UDCA Sales Quantity by Type (2020-2031)
    7.2 North America Drugs of UDCA and t-UDCA Sales Quantity by Application (2020-2031)
    7.3 North America Drugs of UDCA and t-UDCA Market Size by Country
        7.3.1 North America Drugs of UDCA and t-UDCA Sales Quantity by Country (2020-2031)
        7.3.2 North America Drugs of UDCA and t-UDCA Consumption Value by Country (2020-2031)
        7.3.3 United States Market Size and Forecast (2020-2031)
        7.3.4 Canada Market Size and Forecast (2020-2031)
        7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe
    8.1 Europe Drugs of UDCA and t-UDCA Sales Quantity by Type (2020-2031)
    8.2 Europe Drugs of UDCA and t-UDCA Sales Quantity by Application (2020-2031)
    8.3 Europe Drugs of UDCA and t-UDCA Market Size by Country
        8.3.1 Europe Drugs of UDCA and t-UDCA Sales Quantity by Country (2020-2031)
        8.3.2 Europe Drugs of UDCA and t-UDCA Consumption Value by Country (2020-2031)
        8.3.3 Germany Market Size and Forecast (2020-2031)
        8.3.4 France Market Size and Forecast (2020-2031)
        8.3.5 United Kingdom Market Size and Forecast (2020-2031)
        8.3.6 Russia Market Size and Forecast (2020-2031)
        8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific
    9.1 Asia-Pacific Drugs of UDCA and t-UDCA Sales Quantity by Type (2020-2031)
    9.2 Asia-Pacific Drugs of UDCA and t-UDCA Sales Quantity by Application (2020-2031)
    9.3 Asia-Pacific Drugs of UDCA and t-UDCA Market Size by Region
        9.3.1 Asia-Pacific Drugs of UDCA and t-UDCA Sales Quantity by Region (2020-2031)
        9.3.2 Asia-Pacific Drugs of UDCA and t-UDCA Consumption Value by Region (2020-2031)
        9.3.3 China Market Size and Forecast (2020-2031)
        9.3.4 Japan Market Size and Forecast (2020-2031)
        9.3.5 South Korea Market Size and Forecast (2020-2031)
        9.3.6 India Market Size and Forecast (2020-2031)
        9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
        9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America
    10.1 South America Drugs of UDCA and t-UDCA Sales Quantity by Type (2020-2031)
    10.2 South America Drugs of UDCA and t-UDCA Sales Quantity by Application (2020-2031)
    10.3 South America Drugs of UDCA and t-UDCA Market Size by Country
        10.3.1 South America Drugs of UDCA and t-UDCA Sales Quantity by Country (2020-2031)
        10.3.2 South America Drugs of UDCA and t-UDCA Consumption Value by Country (2020-2031)
        10.3.3 Brazil Market Size and Forecast (2020-2031)
        10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa
    11.1 Middle East & Africa Drugs of UDCA and t-UDCA Sales Quantity by Type (2020-2031)
    11.2 Middle East & Africa Drugs of UDCA and t-UDCA Sales Quantity by Application (2020-2031)
    11.3 Middle East & Africa Drugs of UDCA and t-UDCA Market Size by Country
        11.3.1 Middle East & Africa Drugs of UDCA and t-UDCA Sales Quantity by Country (2020-2031)
        11.3.2 Middle East & Africa Drugs of UDCA and t-UDCA Consumption Value by Country (2020-2031)
        11.3.3 Turkey Market Size and Forecast (2020-2031)
        11.3.4 Egypt Market Size and Forecast (2020-2031)
        11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
        11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics
    12.1 Drugs of UDCA and t-UDCA Market Drivers
    12.2 Drugs of UDCA and t-UDCA Market Restraints
    12.3 Drugs of UDCA and t-UDCA Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Drugs of UDCA and t-UDCA and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Drugs of UDCA and t-UDCA
    13.3 Drugs of UDCA and t-UDCA Production Process
    13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Drugs of UDCA and t-UDCA Typical Distributors
    14.3 Drugs of UDCA and t-UDCA Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Drugs of UDCA and t-UDCA Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
 Table 2. Global Drugs of UDCA and t-UDCA Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
 Table 3. Dr. Falk Pharma Basic Information, Manufacturing Base and Competitors
 Table 4. Dr. Falk Pharma Major Business
 Table 5. Dr. Falk Pharma Drugs of UDCA and t-UDCA Product and Services
 Table 6. Dr. Falk Pharma Drugs of UDCA and t-UDCA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 7. Dr. Falk Pharma Recent Developments/Updates
 Table 8. Daewoong Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 9. Daewoong Pharmaceutical Major Business
 Table 10. Daewoong Pharmaceutical Drugs of UDCA and t-UDCA Product and Services
 Table 11. Daewoong Pharmaceutical Drugs of UDCA and t-UDCA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 12. Daewoong Pharmaceutical Recent Developments/Updates
 Table 13. Teva Basic Information, Manufacturing Base and Competitors
 Table 14. Teva Major Business
 Table 15. Teva Drugs of UDCA and t-UDCA Product and Services
 Table 16. Teva Drugs of UDCA and t-UDCA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 17. Teva Recent Developments/Updates
 Table 18. Epic Pharma Basic Information, Manufacturing Base and Competitors
 Table 19. Epic Pharma Major Business
 Table 20. Epic Pharma Drugs of UDCA and t-UDCA Product and Services
 Table 21. Epic Pharma Drugs of UDCA and t-UDCA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 22. Epic Pharma Recent Developments/Updates
 Table 23. Mitsubishi Tanabe Pharma Basic Information, Manufacturing Base and Competitors
 Table 24. Mitsubishi Tanabe Pharma Major Business
 Table 25. Mitsubishi Tanabe Pharma Drugs of UDCA and t-UDCA Product and Services
 Table 26. Mitsubishi Tanabe Pharma Drugs of UDCA and t-UDCA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 27. Mitsubishi Tanabe Pharma Recent Developments/Updates
 Table 28. Lannett Basic Information, Manufacturing Base and Competitors
 Table 29. Lannett Major Business
 Table 30. Lannett Drugs of UDCA and t-UDCA Product and Services
 Table 31. Lannett Drugs of UDCA and t-UDCA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 32. Lannett Recent Developments/Updates
 Table 33. Viatris Basic Information, Manufacturing Base and Competitors
 Table 34. Viatris Major Business
 Table 35. Viatris Drugs of UDCA and t-UDCA Product and Services
 Table 36. Viatris Drugs of UDCA and t-UDCA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 37. Viatris Recent Developments/Updates
 Table 38. Bruschettini Basic Information, Manufacturing Base and Competitors
 Table 39. Bruschettini Major Business
 Table 40. Bruschettini Drugs of UDCA and t-UDCA Product and Services
 Table 41. Bruschettini Drugs of UDCA and t-UDCA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 42. Bruschettini Recent Developments/Updates
 Table 43. Impax Basic Information, Manufacturing Base and Competitors
 Table 44. Impax Major Business
 Table 45. Impax Drugs of UDCA and t-UDCA Product and Services
 Table 46. Impax Drugs of UDCA and t-UDCA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 47. Impax Recent Developments/Updates
 Table 48. Shanghai Pharma Basic Information, Manufacturing Base and Competitors
 Table 49. Shanghai Pharma Major Business
 Table 50. Shanghai Pharma Drugs of UDCA and t-UDCA Product and Services
 Table 51. Shanghai Pharma Drugs of UDCA and t-UDCA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 52. Shanghai Pharma Recent Developments/Updates
 Table 53. Grindeks Basic Information, Manufacturing Base and Competitors
 Table 54. Grindeks Major Business
 Table 55. Grindeks Drugs of UDCA and t-UDCA Product and Services
 Table 56. Grindeks Drugs of UDCA and t-UDCA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 57. Grindeks Recent Developments/Updates
 Table 58. Global Drugs of UDCA and t-UDCA Sales Quantity by Manufacturer (2020-2025) & (K Units)
 Table 59. Global Drugs of UDCA and t-UDCA Revenue by Manufacturer (2020-2025) & (USD Million)
 Table 60. Global Drugs of UDCA and t-UDCA Average Price by Manufacturer (2020-2025) & (US$/Unit)
 Table 61. Market Position of Manufacturers in Drugs of UDCA and t-UDCA, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
 Table 62. Head Office and Drugs of UDCA and t-UDCA Production Site of Key Manufacturer
 Table 63. Drugs of UDCA and t-UDCA Market: Company Product Type Footprint
 Table 64. Drugs of UDCA and t-UDCA Market: Company Product Application Footprint
 Table 65. Drugs of UDCA and t-UDCA New Market Entrants and Barriers to Market Entry
 Table 66. Drugs of UDCA and t-UDCA Mergers, Acquisition, Agreements, and Collaborations
 Table 67. Global Drugs of UDCA and t-UDCA Consumption Value by Region (2020-2024-2031) & (USD Million) & CAGR
 Table 68. Global Drugs of UDCA and t-UDCA Sales Quantity by Region (2020-2025) & (K Units)
 Table 69. Global Drugs of UDCA and t-UDCA Sales Quantity by Region (2026-2031) & (K Units)
 Table 70. Global Drugs of UDCA and t-UDCA Consumption Value by Region (2020-2025) & (USD Million)
 Table 71. Global Drugs of UDCA and t-UDCA Consumption Value by Region (2026-2031) & (USD Million)
 Table 72. Global Drugs of UDCA and t-UDCA Average Price by Region (2020-2025) & (US$/Unit)
 Table 73. Global Drugs of UDCA and t-UDCA Average Price by Region (2026-2031) & (US$/Unit)
 Table 74. Global Drugs of UDCA and t-UDCA Sales Quantity by Type (2020-2025) & (K Units)
 Table 75. Global Drugs of UDCA and t-UDCA Sales Quantity by Type (2026-2031) & (K Units)
 Table 76. Global Drugs of UDCA and t-UDCA Consumption Value by Type (2020-2025) & (USD Million)
 Table 77. Global Drugs of UDCA and t-UDCA Consumption Value by Type (2026-2031) & (USD Million)
 Table 78. Global Drugs of UDCA and t-UDCA Average Price by Type (2020-2025) & (US$/Unit)
 Table 79. Global Drugs of UDCA and t-UDCA Average Price by Type (2026-2031) & (US$/Unit)
 Table 80. Global Drugs of UDCA and t-UDCA Sales Quantity by Application (2020-2025) & (K Units)
 Table 81. Global Drugs of UDCA and t-UDCA Sales Quantity by Application (2026-2031) & (K Units)
 Table 82. Global Drugs of UDCA and t-UDCA Consumption Value by Application (2020-2025) & (USD Million)
 Table 83. Global Drugs of UDCA and t-UDCA Consumption Value by Application (2026-2031) & (USD Million)
 Table 84. Global Drugs of UDCA and t-UDCA Average Price by Application (2020-2025) & (US$/Unit)
 Table 85. Global Drugs of UDCA and t-UDCA Average Price by Application (2026-2031) & (US$/Unit)
 Table 86. North America Drugs of UDCA and t-UDCA Sales Quantity by Type (2020-2025) & (K Units)
 Table 87. North America Drugs of UDCA and t-UDCA Sales Quantity by Type (2026-2031) & (K Units)
 Table 88. North America Drugs of UDCA and t-UDCA Sales Quantity by Application (2020-2025) & (K Units)
 Table 89. North America Drugs of UDCA and t-UDCA Sales Quantity by Application (2026-2031) & (K Units)
 Table 90. North America Drugs of UDCA and t-UDCA Sales Quantity by Country (2020-2025) & (K Units)
 Table 91. North America Drugs of UDCA and t-UDCA Sales Quantity by Country (2026-2031) & (K Units)
 Table 92. North America Drugs of UDCA and t-UDCA Consumption Value by Country (2020-2025) & (USD Million)
 Table 93. North America Drugs of UDCA and t-UDCA Consumption Value by Country (2026-2031) & (USD Million)
 Table 94. Europe Drugs of UDCA and t-UDCA Sales Quantity by Type (2020-2025) & (K Units)
 Table 95. Europe Drugs of UDCA and t-UDCA Sales Quantity by Type (2026-2031) & (K Units)
 Table 96. Europe Drugs of UDCA and t-UDCA Sales Quantity by Application (2020-2025) & (K Units)
 Table 97. Europe Drugs of UDCA and t-UDCA Sales Quantity by Application (2026-2031) & (K Units)
 Table 98. Europe Drugs of UDCA and t-UDCA Sales Quantity by Country (2020-2025) & (K Units)
 Table 99. Europe Drugs of UDCA and t-UDCA Sales Quantity by Country (2026-2031) & (K Units)
 Table 100. Europe Drugs of UDCA and t-UDCA Consumption Value by Country (2020-2025) & (USD Million)
 Table 101. Europe Drugs of UDCA and t-UDCA Consumption Value by Country (2026-2031) & (USD Million)
 Table 102. Asia-Pacific Drugs of UDCA and t-UDCA Sales Quantity by Type (2020-2025) & (K Units)
 Table 103. Asia-Pacific Drugs of UDCA and t-UDCA Sales Quantity by Type (2026-2031) & (K Units)
 Table 104. Asia-Pacific Drugs of UDCA and t-UDCA Sales Quantity by Application (2020-2025) & (K Units)
 Table 105. Asia-Pacific Drugs of UDCA and t-UDCA Sales Quantity by Application (2026-2031) & (K Units)
 Table 106. Asia-Pacific Drugs of UDCA and t-UDCA Sales Quantity by Region (2020-2025) & (K Units)
 Table 107. Asia-Pacific Drugs of UDCA and t-UDCA Sales Quantity by Region (2026-2031) & (K Units)
 Table 108. Asia-Pacific Drugs of UDCA and t-UDCA Consumption Value by Region (2020-2025) & (USD Million)
 Table 109. Asia-Pacific Drugs of UDCA and t-UDCA Consumption Value by Region (2026-2031) & (USD Million)
 Table 110. South America Drugs of UDCA and t-UDCA Sales Quantity by Type (2020-2025) & (K Units)
 Table 111. South America Drugs of UDCA and t-UDCA Sales Quantity by Type (2026-2031) & (K Units)
 Table 112. South America Drugs of UDCA and t-UDCA Sales Quantity by Application (2020-2025) & (K Units)
 Table 113. South America Drugs of UDCA and t-UDCA Sales Quantity by Application (2026-2031) & (K Units)
 Table 114. South America Drugs of UDCA and t-UDCA Sales Quantity by Country (2020-2025) & (K Units)
 Table 115. South America Drugs of UDCA and t-UDCA Sales Quantity by Country (2026-2031) & (K Units)
 Table 116. South America Drugs of UDCA and t-UDCA Consumption Value by Country (2020-2025) & (USD Million)
 Table 117. South America Drugs of UDCA and t-UDCA Consumption Value by Country (2026-2031) & (USD Million)
 Table 118. Middle East & Africa Drugs of UDCA and t-UDCA Sales Quantity by Type (2020-2025) & (K Units)
 Table 119. Middle East & Africa Drugs of UDCA and t-UDCA Sales Quantity by Type (2026-2031) & (K Units)
 Table 120. Middle East & Africa Drugs of UDCA and t-UDCA Sales Quantity by Application (2020-2025) & (K Units)
 Table 121. Middle East & Africa Drugs of UDCA and t-UDCA Sales Quantity by Application (2026-2031) & (K Units)
 Table 122. Middle East & Africa Drugs of UDCA and t-UDCA Sales Quantity by Country (2020-2025) & (K Units)
 Table 123. Middle East & Africa Drugs of UDCA and t-UDCA Sales Quantity by Country (2026-2031) & (K Units)
 Table 124. Middle East & Africa Drugs of UDCA and t-UDCA Consumption Value by Country (2020-2025) & (USD Million)
 Table 125. Middle East & Africa Drugs of UDCA and t-UDCA Consumption Value by Country (2026-2031) & (USD Million)
 Table 126. Drugs of UDCA and t-UDCA Raw Material
 Table 127. Key Manufacturers of Drugs of UDCA and t-UDCA Raw Materials
 Table 128. Drugs of UDCA and t-UDCA Typical Distributors
 Table 129. Drugs of UDCA and t-UDCA Typical Customers


List of Figures
 Figure 1. Drugs of UDCA and t-UDCA Picture
 Figure 2. Global Drugs of UDCA and t-UDCA Revenue by Type, (USD Million), 2020 & 2024 & 2031
 Figure 3. Global Drugs of UDCA and t-UDCA Revenue Market Share by Type in 2024
 Figure 4. t-UDCA Examples
 Figure 5. UDCA Examples
 Figure 6. Global Drugs of UDCA and t-UDCA Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
 Figure 7. Global Drugs of UDCA and t-UDCA Revenue Market Share by Application in 2024
 Figure 8. Gallstone Examples
 Figure 9. Hepatopathy Examples
 Figure 10. Biliary Disease Examples
 Figure 11. Other Examples
 Figure 12. Global Drugs of UDCA and t-UDCA Consumption Value, (USD Million): 2020 & 2024 & 2031
 Figure 13. Global Drugs of UDCA and t-UDCA Consumption Value and Forecast (2020-2031) & (USD Million)
 Figure 14. Global Drugs of UDCA and t-UDCA Sales Quantity (2020-2031) & (K Units)
 Figure 15. Global Drugs of UDCA and t-UDCA Price (2020-2031) & (US$/Unit)
 Figure 16. Global Drugs of UDCA and t-UDCA Sales Quantity Market Share by Manufacturer in 2024
 Figure 17. Global Drugs of UDCA and t-UDCA Revenue Market Share by Manufacturer in 2024
 Figure 18. Producer Shipments of Drugs of UDCA and t-UDCA by Manufacturer Sales ($MM) and Market Share (%): 2024
 Figure 19. Top 3 Drugs of UDCA and t-UDCA Manufacturer (Revenue) Market Share in 2024
 Figure 20. Top 6 Drugs of UDCA and t-UDCA Manufacturer (Revenue) Market Share in 2024
 Figure 21. Global Drugs of UDCA and t-UDCA Sales Quantity Market Share by Region (2020-2031)
 Figure 22. Global Drugs of UDCA and t-UDCA Consumption Value Market Share by Region (2020-2031)
 Figure 23. North America Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 24. Europe Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 25. Asia-Pacific Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 26. South America Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 27. Middle East & Africa Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 28. Global Drugs of UDCA and t-UDCA Sales Quantity Market Share by Type (2020-2031)
 Figure 29. Global Drugs of UDCA and t-UDCA Consumption Value Market Share by Type (2020-2031)
 Figure 30. Global Drugs of UDCA and t-UDCA Average Price by Type (2020-2031) & (US$/Unit)
 Figure 31. Global Drugs of UDCA and t-UDCA Sales Quantity Market Share by Application (2020-2031)
 Figure 32. Global Drugs of UDCA and t-UDCA Revenue Market Share by Application (2020-2031)
 Figure 33. Global Drugs of UDCA and t-UDCA Average Price by Application (2020-2031) & (US$/Unit)
 Figure 34. North America Drugs of UDCA and t-UDCA Sales Quantity Market Share by Type (2020-2031)
 Figure 35. North America Drugs of UDCA and t-UDCA Sales Quantity Market Share by Application (2020-2031)
 Figure 36. North America Drugs of UDCA and t-UDCA Sales Quantity Market Share by Country (2020-2031)
 Figure 37. North America Drugs of UDCA and t-UDCA Consumption Value Market Share by Country (2020-2031)
 Figure 38. United States Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 39. Canada Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 40. Mexico Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 41. Europe Drugs of UDCA and t-UDCA Sales Quantity Market Share by Type (2020-2031)
 Figure 42. Europe Drugs of UDCA and t-UDCA Sales Quantity Market Share by Application (2020-2031)
 Figure 43. Europe Drugs of UDCA and t-UDCA Sales Quantity Market Share by Country (2020-2031)
 Figure 44. Europe Drugs of UDCA and t-UDCA Consumption Value Market Share by Country (2020-2031)
 Figure 45. Germany Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 46. France Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 47. United Kingdom Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 48. Russia Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 49. Italy Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 50. Asia-Pacific Drugs of UDCA and t-UDCA Sales Quantity Market Share by Type (2020-2031)
 Figure 51. Asia-Pacific Drugs of UDCA and t-UDCA Sales Quantity Market Share by Application (2020-2031)
 Figure 52. Asia-Pacific Drugs of UDCA and t-UDCA Sales Quantity Market Share by Region (2020-2031)
 Figure 53. Asia-Pacific Drugs of UDCA and t-UDCA Consumption Value Market Share by Region (2020-2031)
 Figure 54. China Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 55. Japan Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 56. South Korea Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 57. India Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 58. Southeast Asia Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 59. Australia Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 60. South America Drugs of UDCA and t-UDCA Sales Quantity Market Share by Type (2020-2031)
 Figure 61. South America Drugs of UDCA and t-UDCA Sales Quantity Market Share by Application (2020-2031)
 Figure 62. South America Drugs of UDCA and t-UDCA Sales Quantity Market Share by Country (2020-2031)
 Figure 63. South America Drugs of UDCA and t-UDCA Consumption Value Market Share by Country (2020-2031)
 Figure 64. Brazil Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 65. Argentina Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 66. Middle East & Africa Drugs of UDCA and t-UDCA Sales Quantity Market Share by Type (2020-2031)
 Figure 67. Middle East & Africa Drugs of UDCA and t-UDCA Sales Quantity Market Share by Application (2020-2031)
 Figure 68. Middle East & Africa Drugs of UDCA and t-UDCA Sales Quantity Market Share by Country (2020-2031)
 Figure 69. Middle East & Africa Drugs of UDCA and t-UDCA Consumption Value Market Share by Country (2020-2031)
 Figure 70. Turkey Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 71. Egypt Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 72. Saudi Arabia Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 73. South Africa Drugs of UDCA and t-UDCA Consumption Value (2020-2031) & (USD Million)
 Figure 74. Drugs of UDCA and t-UDCA Market Drivers
 Figure 75. Drugs of UDCA and t-UDCA Market Restraints
 Figure 76. Drugs of UDCA and t-UDCA Market Trends
 Figure 77. Porters Five Forces Analysis
 Figure 78. Manufacturing Cost Structure Analysis of Drugs of UDCA and t-UDCA in 2024
 Figure 79. Manufacturing Process Analysis of Drugs of UDCA and t-UDCA
 Figure 80. Drugs of UDCA and t-UDCA Industrial Chain
 Figure 81. Sales Channel: Direct to End-User vs Distributors
 Figure 82. Direct Channel Pros & Cons
 Figure 83. Indirect Channel Pros & Cons
 Figure 84. Methodology
 Figure 85. Research Process and Data Source

Companies Mentioned

Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Viatris
Bruschettini
Impax
Shanghai Pharma
Grindeks